Aratana Therapeutics to Present at Two Upcoming Investor Conferences

LEAWOOD, Kan., Oct. 27, 2016 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, plans to present at the 2016 Credit Suisse Healthcare Conference on Tuesday, November 8 at 8:30 a.m. MT in Scottsdale, Arizona and at Stifel Healthcare Conference 2016 on Wednesday, November 16 at 8:45 a.m. ET in New York City.

Both the Credit Suisse Healthcare Conference and the Stifel Healthcare Conference presentations will be webcast and interested parties may listen live or access the audio link for up to 90 days after the meeting. Presentation slides from the conference will also be available in the Aratana Investor Room.

Aratana Therapeutics logo

 

About Aratana Therapeutics

Aratana Therapeutics is a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for dogs and cats. Aratana believes that it can leverage the investment in the human pharmaceutical industry to bring therapeutics to pets in a capital and time efficient manner. The Company has multiple products approved by the Food and Drug Administration's Center for Veterinary Medicine or licensed by the United States Department of Agriculture. The Company's pipeline includes therapeutic candidates targeting pain, inappetence, cancer, viral diseases, allergy and other serious, unmet or underserved medical needs.  Aratana believes providing innovative options to veterinarians and pet owners will help manage pets' medical needs safely and effectively, result in longer and improved quality of life for pets. For more information, please visit www.aratana.com.

Contacts

For investor inquires:
Craig Tooman
ctooman@aratana.com
(913) 353-1026

For media inquiries:
Rachel Reiff
rreiff@aratana.com
(913) 353-1050

Logo - http://photos.prnewswire.com/prnh/20160425/359503LOGO



 

SOURCE Aratana Therapeutics, Inc.